<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.dmsjournal.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Diabetology &amp; Metabolic Syndrome - Latest Articles</title>
        <link>http://www.dmsjournal.com</link>
        <description>The latest research articles published by Diabetology &amp; Metabolic Syndrome</description>
        <dc:date>2010-03-09T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/14" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/13" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/12" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/11" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/10" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/9" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/8" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/7" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/6" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/5" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/14">
        <title>Prevalence of type 1 diabetes mellitus in Karnal district, Haryana state, India</title>
        <description>Background:
Little work has been done on the prevalence of type 1 diabetes in north India. This paper reports the prevalence of type 1 diabetes in Karnal district of Haryana state,India.Material &amp; Methods: Prevalence of type 1 diabetes was assessed by a hospital-based registry and by analysis of data contributed by chemists and other physicians.
Results:
The overall prevalence of type 1 diabetes in Karnal district is 10.20/100,000 population, with a higher prevalence in urban (26.6/100,000) as compared to rural areas (4.27/100,000). Karnal city, with a population of 222017, has a relatively high prevalence of type 1 diabetes (31.9/100,000).The prevalence in men is higher (11.56/100,000) than in women (8.6/100,000).In the 5 to 16 years age group,the prevalence is 22.22/100,000, while in the 0-5 years age group, prevalence is 3.82/100,000.
Conclusions:
This report highlights the urban-rural and male-female gradient in the prevalence of type 1 diabetes in Karnal, north India.</description>
        <link>http://www.dmsjournal.com/content/2/1/14</link>
                <dc:creator>Sanjay Kalra</dc:creator>
                <dc:creator>Bharti Kalra</dc:creator>
                <dc:creator>Amit Sharma</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:14</dc:source>
        <dc:date>2010-03-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-14</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>14</prism:startingPage>
        <prism:publicationDate>2010-03-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/13">
        <title>Short-term nutritional counseling reduces body mass index, waist circumference, triceps skinfold and triglycerides in women with metabolic syndrome</title>
        <description>Background:
It is recognized that the growing epidemic of metabolic syndrome is related to dietary and lifestyle changes.ObjectiveThe purpose of this study was to evaluate short-term application of nutritional counseling in women with metabolic syndrome.
Methods:
This follow-up study was conducted from September to November 2008 with thirty three women &#8805;35 years old screened clinically for nutritional counseling. Dietary intake was reported, and biochemical and body composition measures were taken at baseline and after three months of follow-up.
Results:
Of the 33 women evaluated, 29 patients completed the study. The prevalence of type 2 diabetes mellitus, hypertension, dyslipidemia, and obesity was high at 38%, 72.4%, 55.2%, and 75.8%, respectively. At the end of three-months of follow-up, a significant decline in body mass index, waist circumference, triceps skinfold, and triglycerides was observed, as was an increase in calcium and vitamin D intake. The multiple regression analysis showed that changes in body mass index, triceps skinfold, waist circumference and triglyceride levels after nutritional intervention were positively associated with changes in anthropometric (loss of body weight) and biochemical (decrease of TG/HDL-c ratio) parameters. Moreover, waist circumference changes were negatively associated with changes in calcium and vitamin D intake.
Conclusion:
Short-term nutritional counseling improved some factors of metabolic syndrome. Moreover, the increases in calcium and vitamin D consumption can be associated with the improvement in markers of metabolic syndrome.</description>
        <link>http://www.dmsjournal.com/content/2/1/13</link>
                <dc:creator>Gustavo Pimentel</dc:creator>
                <dc:creator>Silvia Arimura</dc:creator>
                <dc:creator>Bruno Moura</dc:creator>
                <dc:creator>Maria Silva</dc:creator>
                <dc:creator>Maysa de Sousa</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:13</dc:source>
        <dc:date>2010-02-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-13</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2010-02-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/12">
        <title>Plasma Adrenomedullin level in Egyptian children and Adolescents with type 1 diabetes mellitus: relationship to microvascular complications</title>
        <description>Background:
Adrenomedullin (AM) is known to be elevated in different clinical situations including diabetes mellitus (DM), but its potential role in the pathogenesis of vascular complications in diabetic children and adolescents is to be clarified. Hence, the study aimed at assessment of plasma adrenomedullin levels in children and adolescents with type 1 DM and correlation of these levels with metabolic control and diabetic microvascular complications (MVC).
Methods:
The study was performed in the Diabetes Specialized Clinic, Children&apos;s Hospital of Ain Shams University in Cairo, Egypt. It included 55 diabetic children and adolescents (mean age 13.93 &#177; 3.15 years) who were subdivided into 40 with no MVC and 15 with MVC. Thirty healthy subjects, age-and sex- matched were included as control group (mean age 12.83 &#177; 2.82 years). Patients and controls were assessed for glycosylated hemoglobin (HbA1c) and plasma adrenomedullin assay using ELISA technique.
Results:
Mean plasma AM levels were significantly increased in patients with and without MVC compared to control group, (110.6 pg/mL, 60.25 pg/mL and 39.2 pg/mL respectively) (P &lt; 0.01) with higher levels in those with MVC (P &lt; 0.05). Plasma AM levels were positively correlated with both duration of diabetes (&#961; = 0.703, P &lt; 0.001) and glycemic control (HbA1c) (&#961; = 0.453, P &lt; 0.001).
Conclusion:
Higher plasma AM levels in diabetics particularly in those with MVC &amp; its correlation with diabetes duration and metabolic control may reflect the role of AM in diabetic vasculopathy in the pediatric age group.</description>
        <link>http://www.dmsjournal.com/content/2/1/12</link>
                <dc:creator>Safinaz El Habashy</dc:creator>
                <dc:creator>Randa Matter</dc:creator>
                <dc:creator>Eman El Hadidi</dc:creator>
                <dc:creator>Hala Afifi</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:12</dc:source>
        <dc:date>2010-02-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-12</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2010-02-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/11">
        <title>Insulin resistance and triglyceride/hdlc index are strongly associated with coronary artery disease</title>
        <description>Background:
Insulin-resistance is associated with cardiovascular disease but it is not used as a marker for disease in clinical practice.AimsTo study the association between the homeostatic model assessment (HOMA-IR) and triglyceride/HDLc ratio (TG/HDLc) with the presence of coronary artery disease in patients submitted to cardiac catheterization.
Methods:
In a cross-sectional study, 131 patients (57.0 &#177; 10 years-old, 51.5% men) underwent clinical, laboratory and angiographic evaluation and were classified as No CAD (absence of coronary artery disease) or CAD (stenosis of more than 30% in at least one major coronary artery).
Results:
Prevalence of coronary artery disease was 56.7%. HOMA-IR and TG/HDLc index were higher in the CAD vs No CAD group, respectively: HOMA-IR: 3.19 (1.70-5.62) vs. 2.33 (1.44-4.06), p = 0.015 and TG/HDLc: 3.20 (2.38-5.59) vs. 2.80 (1.98-4.59) p = 0.045) - median (p25-75). After a ROC curve analysis, cut-off values were selected based on the best positive predictive value for each variable: HOMA-IR = 6.0, TG/HDLc = 8.5 and [HOMA-IR&#215;TG/HDLc] = 28. Positive predictive value for coronary artery disease for HOMA-IR&gt;6.0 was 82.6%, for TG/HDLc&gt;8.5 was 85.7% and for [HOMA-IR&#215;TG/HDLc]&gt;28 was 88.0%. Adjusted relative risk (age, gender, diabetes, body mass index, systolic blood pressure) for the presence of coronary artery disease was: for HOMA-IR&gt;6.0, 1.47 (95.CI: 1.06-2.04, p = 0.027), for TG/HDLc&gt;8.5, 1.46 (95% CI:1.07-1.98), p = 0.015) and for [HOMA-IR &#215; TG/HDLc] &gt;28, 1.64 (95%CI: 1.28-2.09), p &lt; 0.001).
Conclusions:
Increased HOMA-IR, TG/HDLc and their product are positively associated with angiographic coronary artery disease, and may be useful for risk stratification as a high-specificity test for coronary artery disease.</description>
        <link>http://www.dmsjournal.com/content/2/1/11</link>
                <dc:creator>Marcello Bertoluci</dc:creator>
                <dc:creator>Alexandre Quadros</dc:creator>
                <dc:creator>Rogerio Sarmento-Leite</dc:creator>
                <dc:creator>Beatriz Schaan</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:11</dc:source>
        <dc:date>2010-02-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-11</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2010-02-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/10">
        <title>Assessment of cognitive status in patients with type 2 diabetes through the mini-mental status examination: a cross-sectional study</title>
        <description>Background:
Diabetes is considered an independent risk factor for cognitive impairment and some studies observed through neuropsychological tests that cognitive disfunction affects both elderly and younger patients with diabetes. The aims of this study were to evaluate the cognitive status of outpatients with type 2 diabetes and to evaluate factors associated with impaired function.
Methods:
A cross-sectional study was conducted in a group of type 2 diabetic outpatients. They were asked to undergo the Mini-Mental State Examination (MMSE) during routine ambulatory visits between April 2006 and January 2007, with the highest pontuation of the test being 30 points. Patients were classified as having possible dementia according to years of study. Exclusion criteria were blindness, illiterately, stroke, Alzheimer disease and psychiatric disorder. Results are presented as median (interquartile range) or mean &#177; SD.
Results:
The study group was composed of 346 type 2 diabetic outpatients (216 females), aged 58,6 &#177; 12,1 years and with duration of diabetes of 12,3 &#177; 9,1 years. Hypertension was present in 77,2%. The total MMSE score achieved was 26 points (16 - 30) and was correlated with years of study (R2 = 0,39, p &lt; 0,001) and &apos;per capita&apos; income (R2 = 0,22, p &lt; 0,0001) and duration of diabetes (R2 = - 0,13, p = 0,01). Patients who needed help to take their medications obtained worst performance in the MMSE (23,16 &#177; 3,55 vs 25,7 &#177; 2,84, p &lt; 0,01) and were more likely to present possible dementia (p &lt; 0,01). Forty two subjects (12.1%) had diagnosis of possible dementia and this was also associated with years of study (p = 0,045). No association was observed between possible dementia and total MMSE scores with A1C levels.
Conclusions:
We conclude that patients with type 2 diabetes should be regularly evaluated for their cognitive function, because duration of disease could be associated with decline in cognition. The early implementation of mini mental which is a simple method of execution can be done to detect early stages of dementia. This test could be an important tool to access the ability of patient to understand their disease and treatment.</description>
        <link>http://www.dmsjournal.com/content/2/1/10</link>
                <dc:creator>Renata Alencar</dc:creator>
                <dc:creator>Roberta Cobas</dc:creator>
                <dc:creator>Marilia Gomes</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:10</dc:source>
        <dc:date>2010-01-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-10</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2010-01-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/9">
        <title>Evaluation of major depression in a routine clinical assessment</title>
        <description>Background:
Major depression is a disorder that significantly worsens a patient&apos;s morbidity and mortality. The association of depression and diabetes is well documented and has clinical impact in diabetes treatment&apos;s outcome. Patients usually aren&apos;t evaluated initially by a psychiatrist, so it is important that non-psychiatrists learn to evaluate major depression and its impact.
Conclusions:
Major depression can and should be evaluated on a routine clinical assessment. Depression&apos;s impact on the patients&apos; quality of life, productivity and social interactions is well documented. The initial diagnosis of depression should lead to its prompt treatment, and it has to be emphasized that the incorrect treatment can lead to worsening of the condition, relapses, recurrences or even chronification of major depression.</description>
        <link>http://www.dmsjournal.com/content/2/1/9</link>
                <dc:creator>Marco Andre Urbach Mezzasalma</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:9</dc:source>
        <dc:date>2010-01-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-9</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2010-01-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/8">
        <title>Construct validity of a continuous metabolic syndrome score in children</title>
        <description>ObjectiveThe primary purpose of this study was to examine the construct validity of a continuous metabolic syndrome score (cMetS) in children. The secondary purpose was to identify a cutpoint value(s) for an adverse cMetS based on receiver operating characteristic (ROC) curve analysis.
Methods:
378 children aged 7 to 9 years were assessed for the metabolic syndrome which was determined by age-modified cutpoints. High-density-lipoprotein cholesterol, triglycerides, the homeostasis assessment model of insulin resistance, mean arterial pressure, and waist circumference were used to create a cMetS for each subject.
Results:
About half of the subjects did not possess any risk factors while about 5% possessed the metabolic syndrome. There was a graded relationship between the cMetS and the number of adverse risk factors. The cMetS was lowest in the group with no adverse risk factors (-1.59 &#177; 1.76) and highest in those possessing the metabolic syndrome (&#8805;3 risk factors) (7.05 &#177; 2.73). The cutoff level yielding the maximal sensitivity and specificity for predicting the presence of the metabolic syndrome was a cMetS of 3.72 (sensitivity = 100%, specificity = 93.9%, and the area of the curve = 0.978 (0.957-0.990, 95% confidence intervals).
Conclusion:
The results demonstrate the construct validity for the cMetS in children. Since there are several drawbacks to identifying a single cut-point value for the cMetS based on this sample, we urge researchers to use the approach herein to validate and create a cMetS that is specific to their study population.</description>
        <link>http://www.dmsjournal.com/content/2/1/8</link>
                <dc:creator>Joey Eisenmann</dc:creator>
                <dc:creator>Kelly Laurson</dc:creator>
                <dc:creator>Katrina DuBose</dc:creator>
                <dc:creator>Bryan Smith</dc:creator>
                <dc:creator>Joseph Donnelly</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:8</dc:source>
        <dc:date>2010-01-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-8</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2010-01-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/7">
        <title>Sedentary subjects have higher PAI-1 and lipoproteins levels than highly trained athletes</title>
        <description>Physical exercise protects against the development of cardiovascular disease, partly by lowering plasmatic total cholesterol, LDL-cholesterol and increased HDL-cholesterol levels. In addition, it is now established that reduction plasmatic adiponectin and increased C-reactive protein (CRP) and plasminogen activator inhibitor-1 (PAI-1) levels play a role in the maintenance of an inflammatory state and in the development of cardiovascular disease. This study aimed to examine plasma lipid profile and inflammatory markers levels in individual with sedentary lifestyle and/or highly trained athletes at rest. Methods: Fourteen male subjects (sedentary lifestyle n = 7 and highly trained athletes n = 7) were recruited. Blood samples were collected after an overnight fast (~12 h). The plasmatic lipid profile (Triglycerides, HDL-cholesterol, LDL-cholesterol, total cholesterol, LDL-oxidized and total cholesterol/HDL-c ratio), glucose, adiponectin, C - reactive protein and PAI-1 levels were determined. Results: Total cholesterol, LDL-cholesterol, TG and PAI-1 levels were lower in highly trained athletes group in relation to sedentary subjects (p &lt; 0.01). In addition, we observed a positive correlation between PAI-1 and total cholesterol (r = 0.78; p &lt; 0.0009), PAI-1 and LDL-c (r = 0.69; p &lt; 0.006) and PAI-1 and TG levels (r = 0.56; p &lt; 0.03). The plasma concentration of adiponectin, CRP, glucose, HDL-cholesterol and total cholesterol/HDL-c ratio levels were not different. These results indicate that lifestyle associated with high intensity and high volume exercise induces changes favourable in the lipid profile and PAI-1 levels and may reduce risk cardiovascular diseases.</description>
        <link>http://www.dmsjournal.com/content/2/1/7</link>
                <dc:creator>Fabio Lira</dc:creator>
                <dc:creator>Jose Rosa</dc:creator>
                <dc:creator>Adriano Lima-Silva</dc:creator>
                <dc:creator>Helio Souza</dc:creator>
                <dc:creator>Erico Caperuto</dc:creator>
                <dc:creator>Marilia Seelaender</dc:creator>
                <dc:creator>Ana Damaso</dc:creator>
                <dc:creator>Lila Oyama</dc:creator>
                <dc:creator>Ronaldo Santos</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:7</dc:source>
        <dc:date>2010-01-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-7</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2010-01-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/6">
        <title>Comparison of venous plasma glycemia and capillary glycemia for the screening of type 2 diabetes mellitus in the Japanese-Brazilian community of Mombuca (Guatapara-SP)</title>
        <description>Background:
To identify the most appropriate cut-off points of fasting glycemia for the screening of diabetes mellitus type 2 (DM2) with the comparison of the properties of capillary glycemia (CG) and venous blood plasma glycemia (PG) in a population of Japanese origin from the community of Mombuca, Guatapar&#225; - SP, Brazil.
Methods:
This was a population-based descriptive cross-sectional study conducted on a sample of 131 individuals of both genders aged 20 years or more (66.8% of the target population). CG was measured with a glucometer in a blood sample obtained from the fingertip and PG was determined by an enzymatic method (hexokinase) in venous blood plasma, after a 10-14 hour fast in both cases. Data were analyzed by the receiver operating characteristic (ROC) curve in order to identify the best cut-off point for fasting glycemia (CG and PG) for the diagnosis of DM, using the 2-hour plasma glycemia &gt; 200 mg/dl as gold - standard.
Results:
The ROC curve revealed that the best cut-off point for the screening of DM was 110 mg/dl for CG and 105 mg/dl for PG, values that would optimize the relation between individuals with positive and false-positive results. The area under the ROC curve was 0.814 for CG (p &lt; 0.01) and 0.836 for PG (p &lt; 0.01).
Conclusions:
The cut-off points of 105 mg/dl(5.8 mmol/l) for PG and of 110 mg/dl(6.1 mmol/l) for CG appear to be the most appropriate for the screening of DM2 in the population under study, with emphasis on the fact that the value recommended for CG is 5 mg/dl higher than that for PG, in contrast to WHO recommendations.</description>
        <link>http://www.dmsjournal.com/content/2/1/6</link>
                <dc:creator>Maria Cristina Foss-Freitas</dc:creator>
                <dc:creator>Regina Andrade</dc:creator>
                <dc:creator>Roberta Figueiredo</dc:creator>
                <dc:creator>Ana Emilia Pace</dc:creator>
                <dc:creator>Edson Martinez</dc:creator>
                <dc:creator>Amaury Dal Fabbro</dc:creator>
                <dc:creator>Laercio Franco</dc:creator>
                <dc:creator>Milton Foss</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:6</dc:source>
        <dc:date>2010-01-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-6</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2010-01-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/5">
        <title>The multiple functions of the endocannabinoid system: a focus on the regulation of food intake.</title>
        <description>Background:
Cannabis sativa (also known as marijuana) has been cultivated by man for more than 5,000 years. However, there was a rise in its use in the 20th century for recreational, religious or spiritual, and medicinal purposes. The main psychoactive constituent of cannabis, whose structure was identified in the 1960&apos;s, is &#916;9-tetrahydrocannabinol. On the other hand, the discovery of cannabinoid receptors and their endogenous agonists took place only very recently. In fact, the first cannabinoid receptor (CB1) was cloned in 1990, followed 3 years later by the characterization of a second cannabinoid receptor (CB2). Since the 19th century, the use of cannabis has been reported to stimulate appetite and increase the consumption of sweet and tasty food, sometimes resulting in significant weight gain. The recent description of the endocannabinoid system, not only in the central nervous system but also in peripheral tissues, points to its involvement in the regulation of appetite, food intake and energy metabolism. Consequently, the pharmacological modulation of the over-activity of this system could be useful in the treatment of the metabolic syndrome.
Conclusions:
The endocannabinoid system has important physiological functions not only in the central nervous system but also in peripheral tissues. The activation of central CB1 receptors, particularly in hypothalamic nuclei and in the limbic system, is involved in the regulation of feeding behavior, and especially in the control of the intake of palatable food. In the periphery, cannabinoid receptors are present in adipocytes, skeletal muscle, gastrointestinal tract and liver, modulating energy metabolism.</description>
        <link>http://www.dmsjournal.com/content/2/1/5</link>
                <dc:creator>Eduardo Tibirica</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:5</dc:source>
        <dc:date>2010-01-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-5</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2010-01-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
